Our intention is to become a China-based international company that leads in the genomics space globally
In Conversation
I foresee a renewed and increased focus on prevention [post-COVID], especially for future pandemics, and on building healthcare systems which are more resilient than efficient
Once you have seen a patient – that without receiving a cell and gene therapy would have died within months – doing well, it has a…
There is a large amount of data available [in healthcare] which has not been used to its full potential
Making medicines available to patients is the name of the game because, in the past, the region had to wait years to get medications from Europe…
We are going to move into an increasingly tech-integrated space where care, content and engagement can be delivered in a variety of ways
I do not think we will ever go back to the way we were before. The pandemic coincided with the beginning of a long conversation we…
2020 saw a lot of innovation, new thinking, and new approaches being developed. Change came fast, but our team did a fantastic job in first embracing…
The digitalisation of healthcare is here to stay, and we can expect the use of technology-based solutions to grow in the post-pandemic era. Tele-consultation and remote…
Switzerland is one of the few biotech hubs that is very diverse and complete in its positioning. Looking at indication-specific research or different modalities, you will…
We see ourselves as the conductor of an orchestra, where all the instruments must play in harmony
Looking at the way diseases manifest and progress might reveal that the solutions around the management of diseases need to be tailored differently
